A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

NCT05482568 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

Sponsor

Jiangsu HengRui Medicine Co., Ltd.